This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
2 Primary · 13 Secondary · Reporting Duration: Up to 50 months
Experimental Treatment
31 Total Participants · 1 Treatment Group
Primary Treatment: RYZ101 + SoC · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: